

August 29, 2014



## Amarantus Appoints Iain Ross to Board of Directors

SAN FRANCISCO and GENEVA, Aug. 29, 2014 (GLOBE NEWSWIRE) --[Amarantus Bioscience Holdings, Inc.](#) (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, today announced the appointment of Mr. Iain Ross to the Company's Board of Directors, Mr. Ross brings over 30 years of biopharmaceutical industry experience to Amaranthus across executive management, investment and directorship roles.

"Amarantus is poised to become a leading company on the cutting edge of neurodegenerative disease diagnostic and drug development," said Iain Ross, a newly-appointed member of the Amaranthus Board of Directors. "The Company has made several key strategic decisions in the last two years that have led to significant appreciation in shareholder value and scientific credibility. As the Company continues on this trajectory, I believe I will be able to bring significant experience and expertise in strategic planning and execution that will pave the way for continued shareholder value creation. I am extremely pleased to be joining Amaranthus as it works toward listing its common shares on a national stock exchange in the United States."

Following a career with multi-national companies including Sandoz, Fisons plc and Hoffman La Roche, Mr. Ross joined the Board of Celltech Group plc in 1991 and was responsible for building Celltech Biologics, the contract manufacturing division which was later sold to Alusuisse Lonza. For the last 18 years he has undertaken a number of start-ups and development stage companies as a board member on behalf of private equity groups and banks, including Quadrant Healthcare plc, Allergy Therapeutics Ltd, Eden Biodesign Ltd, Phadia AB and Silence Therapeutics plc.

Currently he is Chairman of the Board of Ark Therapeutics Group PLC and Biomer Technology Ltd, and is also a Non-Executive Director of Benitec Biopharma Limited, Novogen Limited and Tissue Therapies Ltd each of which is traded on the Australian Securities Exchange. He is a Qualified Chartered Director of the UK Institute of Directors and Vice Chairman of the Council of Royal Holloway, University of London.

"Mr. Ross has an extensive background in biologic drug development, and strategic corporate transactions that have led to significant accretion of shareholder value," said Gerald E. Commissiong, President & CEO of Amaranthus. "As we continue on our path to build a world class company, we believe adding Iain's leadership to our Board, along with his extensive network in Europe and Australia, will bolster our position as a leading emerging growth company and broaden our transactional purview."

**About Amaranthus BioScience Holdings, Inc.**

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. AMBS has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready small molecule indicated for Parkinson's Levodopa induced dyskinesia and Adult ADHD. AMBS has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. AMBS also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). Amarantus operations are located at Janssen Labs @QB3 in San Francisco, CA. For further information please visit [www.Amarantus.com](http://www.Amarantus.com), or connect with the Company on [Facebook](#), [LinkedIn](#), [Twitter](#) and [Google+](#).

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements." These forward-looking statements generally are identified by the words believes," project," expects," anticipates," estimates," intends," strategy," plan," may," will," would," will be," will continue," will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

CONTACT: Amarantus Bioscience Holdings, Inc.:

Robert Farrell  
Chief Financial Officer  
408.737.2734 x 102

and

Aimee Boutcher  
Investor Relations  
408.737.2734 x 101  
[ir@amarantus.com](mailto:ir@amarantus.com)

Source: Amarantus BioScience Holdings, Inc.